Revenue is up. Headcounts are growing. New customers are coming in.
From the outside, everything looks right. The board is energized. The pipeline is moving. By every conventional operating metric, the business appears healthy.
But when a sophisticated buyer sits down in diligence, the story they see is often different from the one leadership believes it’s telling.
Growth and value are not the same thing. The gap between them is quiet, and expensive.
The pattern we see most often in growth-stage healthcare companies: revenue is moving, but the engine driving it was never fully institutionalized. Growth is real. But it’s not durable. And durability is what buyers underwrite.
Successfully stuck: growth without the structural leverage that makes it repeatable, transferable, and worth a premium multiple.
Failure is visible. Failure creates urgency. When a business is struggling, leadership investigates, investors ask hard questions, and gaps get addressed.
Growth does the opposite. When revenue is climbing, the hard questions don't get asked. Momentum becomes a proxy for structural soundness. But it shouldn't.
A company can grow for years on founder effort, personal relationships, and individual performance, and appear completely healthy by every operational measure. Until it doesn't.
That gap surfaces in a transaction. A leadership change. The first real attempt to expand into a new market without the founder in every room. By then, the flexibility to close is narrower, and the valuation impact is already priced in.
Momentum tells you where you've been, but it doesn't tell you whether the engine is built to scale.
There are two kinds of growth in healthcare companies. They produce nearly identical revenue lines in operating mode. They’re worth very different multiples in underwriting mode.
Effort-based growth looks like this:
System-based growth looks like this:
Buyers don't discount effort-based growth because they don't respect the work. They discount it because they can’t underwrite it. You can’t put a founder's relationship network on a balance sheet.
When a PE investment committee or strategic acquirer evaluates a healthcare company, they are not asking whether it grew. They are asking whether the growth is real and asking in the way that matters for what comes next.
Every serious diligence process returns to three core questions, regardless of whether anyone names them explicitly.
PE firms are asking:
Strategic acquirers are asking:
When the honest answer to any of these is unclear, buyers fill in the gaps themselves. They fill them conservatively. That shows up in price, structure, or both.
These patterns don’t appear in a headline revenue number. They appear in the ratios, and experienced buyers know exactly where to look.
None of these signals are catastrophic in isolation. But when two or three appear together, they tell a consistent story: the company isn’t in a growth problem. It’s in a systems problem wearing a growth costume.
That distinction matters enormously when it comes to valuation. What matters even more is how much time remains to address it.
A mid-market health tech company had grown significantly through high-performing direct sales. Revenue was accelerating. The founder was credible, well regarded in the market, and deeply involved in every enterprise deal.
When the acquisition process began, the diligence team started pressing on a few specific areas:
Nothing was inaccurate. Nothing was reckless. But what felt like impressive growth internally looked like structural fragility externally.
The clinical model was sound. The financial performance was real. But the growth engine had never been institutionalized. The multiple reflected that.
The gap between what a business has built and what it’s worth at exit is rarely about the fundamentals. Payer mix, referral infrastructure, revenue concentration, margin profile - those are what they are.
It’s when positioning, proof, and commercial execution are misaligned, that growth slows and valuation risk increases quietly. When they are aligned, the story becomes easier to understand, easier to believe, and easier to underwrite at a premium.
Narrative is not packaging. Commercial infrastructure is not a pre-sale checklist. Both are levers that affect valuation, and both are hardest to move when diligence has already begun.
The earlier you identify where growth is effort-based rather than system-based, the more options you still have to close that gap before it closes your deal.
If you want to understand where your growth story may be creating quiet valuation risk, our Exit Readiness Diagnostic is designed to highlight exactly that - while there’s still time to address it properly.
CTA: If your growth isn’t compounding, it’s quietly capping your valuation. The earlier you identify it, the more options you still have. Book your Exit Readiness Diagnostic.
Revenue growth and valuation strength are not the same thing. Buyers aren't underwriting whether you grew - they're underwriting whether that growth will continue without the people and relationships that drove it. If your messaging varies depending on who is speaking, your positioning hasn't kept pace with how the business has evolved, or your founder is present in every meaningful deal, buyers will price that structural fragility into their offer. As Legacy DNA puts it: narrative debt doesn't appear on a balance sheet. It appears in the offer.
Effort-based growth is driven by founders closing deals, relationships opening doors, and wins that depend on who you know. System-based growth is driven by a repeatable go-to-market motion, consistent positioning, and conversion metrics that compound over time. Both can produce similar revenue numbers in operating mode - but in underwriting mode they are worth very different multiples. Fast growth can command a premium, but only when its durability is verifiable. Buyers can't put a founder's relationship network on a balance sheet, so effort-based growth gets discounted.
Watch for two or more of these patterns together: revenue is climbing but sales cycles aren't shortening; pipeline is growing but conversion rates are flat; headcount is increasing but output per person isn't improving; messaging is evolving but inconsistently across the team. None is catastrophic on its own. Together, they signal a systems problem wearing a growth costume - and experienced buyers know exactly where in the data to find them. What felt like impressive growth internally looks like structural fragility externally.
The gap surfaces during a transaction, a leadership change, or the first attempt to expand without the founder in the room - and by then, the flexibility to close it is significantly narrower. Messaging can be adjusted and decks can be polished, but transferability has to be demonstrated. Diligence is a difficult place to build that case for the first time. Legacy DNA identifies the window that matters as 12 to 36 months before a liquidity event - when there is still time to institutionalize the commercial engine before gaps become valuation adjustments.
Buyers consistently return to the same core questions: Does growth continue without the current team? Is there concentration risk in customers, channels, or key people? Does the model scale across new markets without starting over? Strategic acquirers add: does this growth integrate cleanly, or does it rely on relationships that won't transfer? When those answers are unclear, the consequences are consistent - diligence cycles lengthen, forward projections carry less confidence, and earnouts appear more often as buyers shift risk back onto the seller.
